CN115073353A - 木脂素类衍生物及其制法和其药物组合物与用途 - Google Patents
木脂素类衍生物及其制法和其药物组合物与用途 Download PDFInfo
- Publication number
- CN115073353A CN115073353A CN202110277262.2A CN202110277262A CN115073353A CN 115073353 A CN115073353 A CN 115073353A CN 202110277262 A CN202110277262 A CN 202110277262A CN 115073353 A CN115073353 A CN 115073353A
- Authority
- CN
- China
- Prior art keywords
- compound
- hydrogen
- cancer
- trihalo
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 229930013686 lignan Natural products 0.000 title abstract description 21
- 235000009408 lignans Nutrition 0.000 title abstract description 21
- 150000005692 lignans Chemical class 0.000 title abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 13
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 6
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 6
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 6
- 208000005017 glioblastoma Diseases 0.000 claims abstract description 5
- 201000007270 liver cancer Diseases 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 4
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 4
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 4
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 3
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 201000001441 melanoma Diseases 0.000 claims abstract description 3
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims abstract description 3
- -1 methylamino, methanesulfonyl Chemical group 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 150000002431 hydrogen Chemical class 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 125000003545 alkoxy group Chemical group 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 claims description 24
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 23
- 239000000460 chlorine Substances 0.000 claims description 22
- 229910052731 fluorine Inorganic materials 0.000 claims description 19
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 14
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 14
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 239000011737 fluorine Substances 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 150000003457 sulfones Chemical class 0.000 claims description 8
- 150000003462 sulfoxides Chemical class 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 150000007530 organic bases Chemical class 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 2
- 241001106041 Lycium Species 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 61
- 239000007858 starting material Substances 0.000 description 51
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- 238000004896 high resolution mass spectrometry Methods 0.000 description 29
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 16
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 14
- GFUDGVLCQPGXJY-UHFFFAOYSA-N 5-fluoroindol-2-one Chemical compound C1=C(F)C=CC2=NC(=O)C=C21 GFUDGVLCQPGXJY-UHFFFAOYSA-N 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 11
- XVNRCKAGJNMGRR-UHFFFAOYSA-N 5-methoxyindol-2-one Chemical compound C1=C(OC)C=CC2=NC(=O)C=C21 XVNRCKAGJNMGRR-UHFFFAOYSA-N 0.000 description 10
- YFBXTDAYOYBAJI-UHFFFAOYSA-N 5-methylindol-2-one Chemical compound C1=C(C)C=CC2=NC(=O)C=C21 YFBXTDAYOYBAJI-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229910020314 ClBr Inorganic materials 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229940126545 compound 53 Drugs 0.000 description 7
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 6
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 6
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 6
- 235000012141 vanillin Nutrition 0.000 description 6
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 5
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 5
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 5
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 5
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 5
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 229940127113 compound 57 Drugs 0.000 description 5
- 229940125900 compound 59 Drugs 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000009076 src-Family Kinases Human genes 0.000 description 5
- 108010087686 src-Family Kinases Proteins 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000003964 Histone deacetylase Human genes 0.000 description 4
- 108090000353 Histone deacetylase Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000004049 epigenetic modification Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DGSQMAWMWINPRH-UHFFFAOYSA-N 1-bromo-1-phenylethanol Chemical compound CC(O)(Br)C1=CC=CC=C1 DGSQMAWMWINPRH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ZLMUFCNWTPSOSN-UHFFFAOYSA-N 4-hydroxy-3-(trifluoromethyl)benzaldehyde Chemical compound OC1=CC=C(C=O)C=C1C(F)(F)F ZLMUFCNWTPSOSN-UHFFFAOYSA-N 0.000 description 2
- RJVMELHDBATWDK-UHFFFAOYSA-N 5-fluoro-3h-1-benzofuran-2-one Chemical compound FC1=CC=C2OC(=O)CC2=C1 RJVMELHDBATWDK-UHFFFAOYSA-N 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108060006706 SRC Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- WPGAERROKPAEPK-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-hydroxypropan-1-one Chemical compound CC(O)C(=O)C1=CC=C(F)C=C1 WPGAERROKPAEPK-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- ACZGCWSMSTYWDQ-UHFFFAOYSA-N 3h-1-benzofuran-2-one Chemical class C1=CC=C2OC(=O)CC2=C1 ACZGCWSMSTYWDQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000058017 Enhancer of Zeste Homolog 2 Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100389970 Homo sapiens EZH2 gene Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- DDKMFOUTRRODRE-UHFFFAOYSA-N chloromethanone Chemical compound Cl[C]=O DDKMFOUTRRODRE-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 150000002475 indoles Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229930182783 neolignan Natural products 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950009195 phenylpropanol Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QROGIFZRVHSFLM-UHFFFAOYSA-N prop-1-enylbenzene Chemical group CC=CC1=CC=CC=C1 QROGIFZRVHSFLM-UHFFFAOYSA-N 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
本发明属于医药技术领域，公开了木脂素类衍生物及其制法和药物组合物与用途。具体涉及式(I)化合物或其异构体及其药学上可接受的盐，以及其制备方法。一种新的药物组合物，包括有效剂量的式(I)化合物和药效学上可接受的载体。本发明还公开了这类化合物在预防和/或治疗免疫失调，和/或肿瘤疾病方面的的应用。所述的肿瘤包括神经胶质母细胞瘤、黑色素瘤、胃癌、肺癌、乳腺癌、肾癌、肝癌、口腔表皮癌、***、卵巢癌、胰腺癌、***癌、结肠癌、直肠腺癌。
Description
技术领域
本发明涉及木脂素类衍生物，其可药用盐，其多晶和共晶，其同样生物功能的前体或衍生物/探针，其制备方法，含它们的药物组合物，及其作为药物，尤其作为预防/抗肿瘤药物的用途，属于医药技术领域。
背景技术
世界卫生组织国际癌症研究机构(IARC)发布了2020年全球最新癌症负担数据。2020年全球新发癌症病例1929万例，其中中国新发癌症457万人，占全球23.7％，由于中国是世界第一人口大国，癌症新发人数远超世界其他国家。癌症新发人数前十的国家分别是：中国457万，美国228万，印度132万，日本103万，德国63万，巴西59万，俄罗斯59万，法国47万，英国46万，意大利42万。抗击癌症，并不仅仅是中国将面临的严峻问题，同时也是全球面临的严峻问题。
医学数据表明，炎症是导致肿瘤的危险因素。例如，***中由于***瘤病毒感染所致的患者较多；胃幽门螺杆菌的感染有增加胃癌风险的趋势；慢性肝炎也可能是诱发肝癌的直接原因。其它因素，如自身免疫性肠病与结肠癌密切相关，空气中的PM2.5也是诱发肺癌的黑手。肿瘤被定义为一种和心脏病、慢性呼吸***疾病或者糖尿病一样非传染性的疾病。它们大多是长时间的慢性疾病，进展比较缓慢。炎症和肿瘤的相关性是最早在1800年前由Galenus提出的，很多研究已经证实持续的炎症可以使病变从感染或者自身免疫性的炎症进展为肿瘤。
木脂素是一类从裸子植物和被子植物中分离得到的天然产物，其天然组分多数以游离状态存在，也有些与糖结合成苷存在于植物的木部和树脂中。木脂素类化合物广义上可分为二大类，即木脂素类和新木脂素类。木脂素偏亲脂性，不易溶于水，能溶于有机溶剂，少数木脂素与糖结合成苷后水溶性增大。大多数木脂素具有光化学活性，遇酸异构化。木脂素类化合物具有多方面生物活性，如：抗肿瘤，[Xu D,Lu Q,Hu X.Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol[J].Cancer Letters,2006,243(2):274-280]抗病毒，抗菌，抗氧化，保护心脑血管等活性，其有非常大的研究前景，我们长期从事木脂素类天然产物的合成，结构简化与优化，进而发现比原天然产物具有更好肿瘤抑制活性，更低毒性的先导物，而进一步成为抗肿瘤药物。
此发明内容所设计的木脂素类衍生物在抗肿瘤潜在的靶点概括如下：
内皮生长因子受体(EGFR)：EGFR的突变活化是导致肿瘤细胞异常生物学活动的重要因素，其中EGFR中T790M突变是一个碱基对发生从胞嘧啶核苷(C)到胸腺嘧啶(T)的改变，即EGFR酪氨酸激酶功能中790位点的苏氨酸被蛋氨酸取代，这种突变可使得EGFR重新处于被激活状态，从而导致酪氨酸激酶抑制剂(TKI)产生耐药性。而我们将此突变后的蛋白与此类天然产物以及衍生物通过计算机辅助设计的方法对接后发现，此类化合物的打分都很高，提示：此类木脂素衍生物可以成为此靶点的筛选候选物。
c-Src蛋白：酪氨酸激酶(Tyrosine protein kinase，TPK)一种，属于胞质非受体类，现已被证明是细胞内信号传导过程(略)中介分子，通过与多种不同受体蛋白相互作用，在细胞生长、增殖、分化、运动和凋亡等生理过程中起着重要调节作用.c-src基因在真核细胞内普遍存在，并且在肿瘤细胞中过量表达，被认(略)生、发展以及转移等密切相关.关于c-Src抑制剂研究也渐成热点，在临床治疗上具有广阔前景.利用基因工程方法大量表达c-Src蛋白，能够大大提高c-Src抑制剂筛选效率，同时为深入研究c-Src抑制剂作用机制提供了可能.
细胞周期蛋白依赖激酶CDK2：CDK2是蛋白质激酶家族中的一员，依赖与细胞周期蛋白的结合来执行细胞周期有序进行中的关键功能。不同的CDK周期蛋白质复合物使特异的靶蛋白质磷酸化而激发细胞周期各期的顺利进行。当缺乏细胞周期蛋白质或CDK抑制物存在时，它们即失去活性，细胞增殖停滞，甚至死亡。CDK通过调节靶蛋白磷酸化而调控细胞周期的运转。
组蛋白-赖氨酸N-甲基转移酶EZH2：EZH2是一个由人类EZH2基因所编码的酶。已鉴定该基因转录出的两种转录物变异体编码不同的亚型；基因序列改变与表观遗传修饰异常有本质的不同。因为DNA序列一旦发生突变，基因就难以修复或变异的基因产物也难以消除。但是表观遗传修饰异常能潜在性地被其相关染色质修饰酶类的抑制剂所逆转。因此，明确肿瘤细胞中的表观遗传修饰酶类的作用机制显得十分重要，进而为阻止表观遗传修饰变异提供相应治疗手段。目前EZH2抑制剂并未有上市药物，共有五种药物正在临床一期，二期研究中。
组蛋白去乙酰化酶(histone deacetylase,HDAC)：一类蛋白酶,对染色体的结构修饰和基因表达调控发挥着重要的作用。一般情况下,组蛋白的乙酰化有利于DNA与组蛋白八聚体的解离，核小体结构松弛，从而使各种转录因子和协同转录因子能与DNA结合位点特异性结合，激活基因的转录。在细胞核内，组蛋白乙酰化与组蛋白去乙酰化过程处于动态平衡，并由组蛋白乙酰化转移酶(histone acetyltransferase,HAT)和组蛋白去乙酰化酶(histone deacetylase,HDAC)共同调控。
Src激酶：一种非受体型蛋白激酶,其广泛存在于癌细胞中,并在细胞生长、增殖的各个过程中都起到重要作用,如基因转录、细胞分化、迁移、血管生成、防止细胞凋亡等等,Src抑制剂的研究成为抗肿瘤药物研究的热点。目前已有一系列Src抑制剂处于临床研究阶段。
癌症免疫治疗是一种越来越有效的癌症治疗策略，T细胞在免疫治疗中起着关键作用，其功能决定了免疫治疗的疗效，T细胞的生存和发育受到TCR信号的影响，而TCR信号通路依赖于Src家族激酶(SFK)。Lck是SFK的重要成员，在T细胞的大部分生命周期中都有表达。此外，Lck在激活TCR信号通路以激活T细胞中发挥重要作用。CSK是SFK的关键调节器，其对Lck(Tyr505)的磷酸化使Lck失活，后者通过TCR抑制T细胞活化。因此，CSK和p-Lck(Tyr505)可能是未来免疫调节治疗的有效靶点。
尽管木脂素类天然产物已被证实具有如上的活性作用，但其确切的作用机制以及在人体内的药物代谢动力学以及药效学需要进一步的研究，由于其亲酯性较大，不易溶于水，因此，本发明提出用引入极性分子到苯丙醇或者苯丙稀的结构中，得到其结构衍生物，并研究其药物作用方式以及可用来治疗的疾病，尤其是炎症相关、肿瘤、免疫调节等。
发明内容
本发明要解决的技术问题是提供具有优良疗效且毒性低的具有抗炎、抗肿瘤活性的木脂素类衍生物，其异构体，其可药用盐，其前药，其多晶或共晶。
本发明要解决的另一技术问题是提供这类化合物的制备方法。
本发明要解决的又一技术问题是提供含有这类化合物的药物组合物。
本发明要解决的再一技术问题是提供这类化合物在制备抗/预防肿瘤，以及与免疫相关疾病的药物中的应用。
为解决本发明的技术问题，采用如下技术方案：
式(I)化合物或其异构体及其药学上可接受的盐；
R1和R2独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，C1-6烷氧羰基，C1-6烷羰基氧基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-6烷基，C1-6烷氧基，三卤C1-6烷基，三卤C1-6烷氧基；
或R1和R2选自-O(CH2)nO-，并与其取代的苯基相连成环；n选自1、2或3；
R3和R4独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，C1-6烷氧羰基，C1-6烷羰基氧基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-6烷基，C1-6烷氧基，三卤C1-6烷基，三卤C1-6烷氧基；
R5选自氢，C1-6烷基，C1-6烷氧基甲基，C0-6烷基胺基；
R6选自氢，羟基，C0-6烷基胺基，C1-6烷羰基氧基，C1-6烷氧基羰基，O＝；
R7，R8，R9，R10，R11独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-6烷基，C1-6烷氧基，三卤C1-6烷基，三卤C1-6烷氧基，C1-6烷氧羰基，C1-6烷羰基氧基，C1-5烷酰基，C1-6烷氧基亚甲基氧基；
或R8和R9选自-O(CH2)n’O-，并与其取代的苯基相连成环；n’选自1、2或3；
三卤C1-6烷基和三卤C1-6烷氧基中三卤指的是含3个卤素，包括F3C1-6烷基、Br3C1-6烷基、Cl3C1-6烷基、I3C1-6烷基、F2BrC1-6烷基、F2ClC1-6烷基、F2IC1-6烷基、FBr2C1-6烷基、FCl2C1-6烷基、FI2C1-6烷基、ClBr2C1-6烷基、ICl2C1-6烷基、ClI2C1-6烷基；F3C1-6烷氧基、Br3C1-6烷氧基、Cl3C1-6烷氧基、I3C1-6烷氧基、F2BrC1-6烷氧基、F2ClC1-6烷氧基、F2IC1-6烷氧基、FBr2C1-6烷氧基、FCl2C1-6烷氧基、FI2C1-6烷基、ClBr2C1-6烷氧基、ICl2C1-6烷氧基、ClI2C1-6烷氧基；
优选F3C1-4烷基、Br3C1-4烷基、Cl3C1-4烷基、I3C1-4烷基、F2BrC1-4烷基、F2ClC1-4烷基、F2IC1-4烷基、FBr2C1-4烷基、FCl2C1-4烷基、FI2C1-4烷基、ClBr2C1-4烷基、ICl2C1-4烷基、ClI2C1-4烷基；F3C1-4烷氧基、Br3C1-4烷氧基、Cl3C1-4烷氧基、I3C1-4烷氧基、F2BrC1-4烷氧基、F2ClC1-4烷氧基、F2IC1-4烷氧基、FBr2C1-4烷氧基、FCl2C1-4烷氧基、FI2C1-4烷基、ClBr2C1-4烷氧基、ICl2C1-4烷氧基、ClI2C1-4烷氧基；
最优选F3C、F3CCH2、Br3C、Br3CCH2、Cl3C、Cl3CCH2、I3C、I3CCH2、F2BrC、F2BrCCH2、F2ClC、F2ClCCH2、F2IC、F2ICCH2、FBr2C、FBr2CCH2、FCl2C、FCl2CCH2、FI2C、FI2CCH2、ClBr2C、ClBr2CCH2、ICl2C、ICl2CCH2、ClI2C、ClI2CCH2；F3CO、F3CCH2O、Br3CO、Br3CCH2O、Cl3CO、Cl3CCH2O、I3CO、I3CCH2O、F2BrCO、F2BrCCH2O、F2ClCO、F2ClCCH2O、F2ICO、F2ICCH2O、FBr2CO、FBr2CCH2O、FCl2CO、FCl2CCH2O、FI2CO、FI2CCH2O、ClBr2CO、ClBr2CCH2O、ICl2CO、ICl2CCH2O、ClI2CO、ClI2CCH2O；
X选自O，NH；
Y选自O，NH，S，亚砜，砜。
在通式(I)的衍生物的实施方案中：
优选的R1，R2独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-4烷基，C1-4烷氧基，三卤C1-4烷基，三卤C1-4烷氧基，C1-4烷氧羰基，C1-4烷羰基氧基，C1-3烷酰基，C1-4烷氧基亚甲基氧基；
优选的R1，R2或选自-O(CH2)n’O-，并与其取代的苯基相连成环；n选自1、2或3；
优选的R3和R4独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，C1-4烷氧羰基，C1-4烷羰基氧基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-4烷基，C1-4烷氧基，三卤C1-4烷基，三卤C1-4烷氧基；
优选的R5选自氢，C1-4烷基，C1-4烷氧基甲基，C0-4烷基胺基；
优选的R6选自氢，羟基，C0-4烷基胺基，C1-4烷羰基氧基，C1-4烷氧基羰基，O＝；
优选的R7，R8，R9，R10，R11独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-4烷基，C1-4烷氧基，三卤C1-4烷基，三卤C1-4烷氧基，C1-4烷氧羰基，C1-4烷羰基氧基，C1-3烷酰基，C1-4烷氧基亚甲基氧基，
优选的R8和R9或选自-O(CH2)n’O-，并与其取代的苯基相连成环；n’选自1、2或3；
优选的X选自O，NH；
优选的Y选自O，NH，S，亚砜，砜。
在通式(I)的衍生物的实施方案中：
更优选的R1，R2独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，甲基，乙基，甲氧基，乙氧基，三卤C1-2烷基，三卤C1-2烷氧基，甲氧羰基，乙氧羰基，甲酰基，乙酰基，丙酰基，丁酰基，戊酰基，异丁酰基，2-甲基丁酰基，C1-2烷氧基亚甲基氧基；
更优选的R1，R2或选自-OCH2O-，-OCH2CH2O-并与其取代的苯基相连成环；
更优选的R3和R4独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲氧羰基，乙氧羰基，C1-2烷羰基氧基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，甲基，乙基，甲氧基，乙氧基，三卤C1-2烷基，三卤C1-2烷氧基；
更优选的R5选自氢，C1-2烷基，C1-2烷氧基甲基，C0-2烷基胺基；
更优选的R6选自氢，羟基，O＝，C0-2烷基胺基，C1-2烷氧基羰基，C1-2烷羰基氧基；
更优选的R7，R8，R9，R10，R11独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，甲基，乙基，甲氧基，乙氧基，三卤C1-2烷基，三卤C1-2烷氧基，甲氧羰基，乙氧羰基，甲酰基，乙酰基，丙酰基，丁酰基，戊酰基，异丁酰基，2-甲基丁酰基，C1-2烷氧基亚甲基氧基；
更优选的R8和R9或选自-OCH2O-，-OCH2CH2O-并与其取代的苯基相连成环；
更优选的X选自O，NH；
更优选的Y选自O，NH，S，亚砜，砜。
在通式(I)的衍生物的实施方案中：
最优选的R1，R2独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，甲基，乙基，甲氧基，乙氧基，三氟甲基，三氟甲氧基，甲氧羰基，甲酰基，乙酰基，丙酰基，丁酰基，戊酰基，异丁酰基，甲氧基亚甲基氧基；
最优选的R1，R2或选自-OCH2O-，-OCH2CH2O-，并与其取代的苯基相连成环；
最优选的R3和R4独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲氧羰基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，甲基，乙基，甲氧基，乙氧基，三氟甲基，三氟甲氧基；
最优选的R5选自氢，甲基，乙基，甲氧基甲基，氨基；
最优选的R6选自氢，羟基，O＝，氨基，C1-2烷羰基氧基；
最优选的R7，R8，R9，R10，R11独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，甲基，乙基，甲氧基，乙氧基，三氟甲基，三氟甲氧基，甲氧羰基，甲酰基，乙酰基，丙酰基，丁酰基，戊酰基，异丁酰基，甲氧基亚甲基氧基；
最优选的R8和R9或选自-OCH2O-，-OCH2CH2O-，并与其取代的苯基相连成环；
最优选的X选自O，NH；
最优选的Y选自O，NH，S，亚砜，砜。
最优选的化合物，包括但不限定于如下化合物
在本发明中，术语“卤素"是指氟、氯、溴、碘。
根据本发明，式(I)化合物可以异构体的形式存在，式(I)化合物连接R5，R6基团的碳的构型可为R或S构型。
本发明包括所有可能的立体异构体以及两种或多种异构体的混合物。
如果存在顺/反异构体，本发明涉及顺式形式和反式形式以及这些形式的混合物，如果需要单一异物体可根据常规方法分离或通过立体选择合成制备。
本发明还公开了制备本发明化合物的方法，包括如下路线步骤：
i:取代；ii:缩合；
A:式(II)化合物在有机碱，如吡啶，哌啶，二异丙胺，乙二胺等；无机碱，如氢氧化钠，氢氧化钾，氢氧化锂，碳酸铯，碳酸钾等碱性条件下与式(III)化合物反应生成式(IV)化合物；
B:式(IV)化合物在有机碱，如吡啶，哌啶，二异丙胺，乙二胺等；无机碱，如氢氧化钠，氢氧化钾，氢氧化锂，碳酸铯，碳酸钾等碱性条件下于甲醇，乙醇，异丙醇，丁醇等醇溶剂中于40℃-70℃加热反应得到式(I)化合物；
其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，X，Y如权利要求1-6任一项所定义；Z选自：羟基，氯，溴，碘，对甲苯磺酰基，甲磺酰基。
式(I)化合物或其异构体及其药学上可接受的盐包括：盐酸盐，氢溴酸盐，磷酸盐，硫酸盐，甲磺酸盐，对甲苯磺酸盐，乙酸盐，三氟乙酸盐，水杨酸盐，氨基酸盐，枸杞酸盐，马来酸盐，酒石酸盐，富马酸盐，柠檬酸盐，乳酸盐，钠盐，钾盐，钙盐，镁盐，锂盐，铵盐和能提供生理上可接受的阳离子的有机碱的盐，如甲胺，二甲胺，三甲胺，哌啶，吗啉及三(2-羟乙基)胺的盐。本发明专利的所有盐都可以采用常规方法制备。另外，式(I)化合物溶剂化物和其盐的制备过程中，不同结晶条件可能出现多晶或共晶。
本发明再一方面还涉及一种药物组合物，包括有效剂量的本发明化合物和药效学上可接受的载体。该药物组合物可根据本领域公知的方法制备。可通过将本发明化合物与一种或多种药学上可接受的固体或液体赋形剂和/或辅剂结合，制成适于人或动物使用的任何剂型。本发明化合物在其药物组合物中的含量通常为0.1-95重量％。
本发明化合物或含有它的药物组合物可以单位剂量形式给药，给药途径可为肠道或非肠道，如口服、静脉注射、肌肉注射、皮下注射、鼻腔、口腔粘膜、眼、肺和呼吸道、皮肤、***、直肠等。
给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂(包括真溶液和胶体溶液)、乳剂(包括o/w型、w/o型和复乳)、混悬剂、注射剂(包括水针剂、粉针剂和输液)、滴眼剂、滴鼻剂、洗剂和搽剂等；固体剂型可以是片剂(包括普通片、肠溶片、含片、分散片、咀嚼片、泡腾片、口腔崩解片)、胶囊剂(包括硬胶囊、软胶囊、肠溶胶囊)、颗粒剂、散剂、微丸、滴丸、栓剂、膜剂、贴片、气(粉)雾剂、喷雾剂等；半固体剂型可以是软膏剂、凝胶剂、糊剂等。
本发明化合物可以制成普通制剂、也制成是缓释制剂、控释制剂、靶向制剂及各种微粒给药***。
为了将本发明化合物制成片剂，可以广泛使用本领域公知的各种赋形剂，包括稀释剂、黏合剂、润湿剂、崩解剂、润滑剂、助流剂。稀释剂可以是淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素、硫酸钙、磷酸氢钙、碳酸钙等；湿润剂可以是水、乙醇、异丙醇等；粘合剂可以是淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、微晶纤维素、***胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯吡咯烷酮、聚乙二醇等；崩解剂可以是干淀粉、微晶纤维素、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、羧甲基淀粉钠、碳酸氢钠与枸橼酸、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基磺酸钠等；润滑剂和助流剂可以是滑石粉、二氧化硅、硬脂酸盐、酒石酸、液体石蜡、聚乙二醇等。
还可以将片剂进一步制成包衣片，例如糖包衣片、薄膜包衣片、肠溶包衣片，或双层片和多层片。
为了将给药单元制成胶囊剂，可以将有效成分本发明化合物与稀释剂、助流剂混合，将混合物直接置于硬胶囊或软胶囊中。也可将有效成分本发明化合物先与稀释剂、黏合剂、崩解剂制成颗粒或微丸，再置于硬胶囊或软胶囊中。用于制备本发明化合物片剂的各稀释剂、黏合剂、润湿剂、崩解剂、助流剂品种也可用于制备本发明化合物的胶囊剂。
为将本发明化合物制成注射剂，可以用水、乙醇、异丙醇、丙二醇或它们的混合物作溶剂并加入适量本领域常用的增溶剂、助溶剂、pH调剂剂、渗透压调节剂。增溶剂或助溶剂可以是泊洛沙姆、卵磷脂、羟丙基-β-环糊精等；pH调剂剂可以是磷酸盐、醋酸盐、盐酸、氢氧化钠等；渗透压调节剂可以是氯化钠、甘露醇、葡萄糖、磷酸盐、醋酸盐等。如制备冻干粉针剂，还可加入甘露醇、葡萄糖等作为支撑剂。
此外，如需要，也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂或其它添加剂。
为达到用药目的，增强治疗效果，本发明的药物或药物组合物可用任何公知的给药方法给药。
根据本发明，式(I)化合物或其异构体及其药学上可接受的盐在抗肿瘤中显示出优良效果。因而可作为抗肿瘤药用于动物，优选用于哺乳动物，特别是人。本发明的化合物可用于制备预防和/或***的药物中的应用。所述的肿瘤选自胶质母细胞瘤、黑色素瘤、胃癌、肺癌、乳腺癌、肾癌、肝癌、口腔上皮癌、***、卵巢癌、胰腺癌、***癌、结肠癌或直肠腺癌。优选的肿瘤选自肝癌。
本发明化合物药物组合物的给药剂量依照所要预防或治疗疾病的性质和严重程度，患者或动物的个体情况，给药途径和剂型等可以有大范围的变化。一般来讲，本发明化合物的每天的合适剂量范围为0.001-150mg/Kg体重，优选为0.1-100mg/Kg体重，更优选为1-70mg/Kg体重，最优选为2-30mg/Kg体重。上述剂量可以一个剂量单位或分成几个剂量单位给药，这取决于医生的临床经验以及包括运用其它治疗手段的给药方案。
本发明的化合物或组合物可单独服用，或与其他治疗药物或对症药物合并使用。当本发明的化合物与其它治疗药物存在协同作用时，应根据实际情况调整它的剂量。
本发明的优点
本发明的化合物是木脂素类的衍生物，此类衍生物与以往的结构改造多有不同，引入取代的吲哚环或取代的苯并呋喃酮而得到新型衍生物。此类化合物对与多个靶点蛋白都有较好的结合，并且具有较好的生物利用度，可用于多种人类恶性肿瘤的治疗，以及肿瘤的预防，其中所述的肿瘤疾病是肺癌、肾癌、肝癌、胰腺癌、结肠癌、膀胱癌、乳腺癌、卵巢癌、及胶质母细胞瘤、白血病、头颈部癌。在炎症治疗中也觉有较好的效果。
具体实施方式
下面的实施例及药物活性实验用来进一步说明本发明，但这并不意味着对本发明的任何限制。
下面的实施例用来解释本发明，但对本发明无任何限制。
使用的原料为已知化合物或按已知方法制备。
步骤A:
(450mg,3mmol)香草醛，(1.2g,4.38mmol)3，4，5-三甲氧基溴代苯乙醇，(1.65g,12mmol)碳酸钾，于20mL DMF中，50℃反应4h，冷却至室温后加入乙酸乙酯和水，分液，取有机相，无水硫酸钠干燥，过滤，浓缩，柱层析(PE:EA＝5：1)得0.63g化合物51，白色固体，收率60.5％。
1H NMR(400MHz,CDCl3)δ9.85(s,1H),7.42-7.44(m,2H),6.96(d,J＝8.8Hz,1H),6.55(s,2H),4.29(t,J＝7.2Hz,2H),3.93(s,3H),3.86(s,6H),3.83(s,3H),3.13(t,J＝7.2Hz,2H)；
13C NMR(100MHz,CDCl3)δ190.8,153.7,153.2,149.8,136.8,133.4,130.1,126.7,111.4,109.3,106.1,99.9,69.7,60.8,56.0,56.0,35.9.
以(300mg,2mmol)香草醛为原料，采用与制备化合物51相似操作步骤，与(402mg,2mmol)4-氟溴代苯乙醇在碳酸钾(1.1g,8mmol),10mL DMF中反应得到化合物52，305mg白色固体，收率55.7％。
1H NMR(400MHz,CDCl3)δ9.80(s,1H),7.37-7.39(m,2H),7.20-7.23(m,2H),6.89-6.99(m,3H),4.21(t,J＝7.2Hz,2H),3.89(s,3H),3.12(t,J＝7.2Hz,2H)；
13C NMR(100MHz,CDCl3)δ190.9,163.0,160.6,153.8,149.9,133.2,130.6,130.2,126.7,115.5,115.3,111.6,109.5,69.7,56.1,34.8.
以(300mg,2mmol)香草醛为原料，采用与制备化合物51相似操作步骤，与(960mg,4mmol)3,4-二甲氧基溴代苯乙醇在碳酸钾(1.1g,8mmol),10mLDMF中反应得到化合物53，445mg白色固体，收率70.4％。
1HNMR(400MHz,CDCl3)δ9.85(s,1H),7.42-7.44(m,2H),6.94-6.96(m,1H),6.88(m,1H),6.83(m,2H),4.27(t,J＝7.2Hz,2H),3.93(s,3H),3.89(s,3H),3.87(s,3H),3.14(t,J＝7.2Hz,2H)；
13C NMR(100MHz,CDCl3)δ190.9,153.8,149.8,148.9,147.8,130.1,130.1,126.8,120.9,112.5,111.4,111.3,109.3,70.0,56.0,55.9,55.8,35.1.
以(300mg,2mmol)香草醛为原料，采用与制备化合物51相似操作步骤，与(800mg,4mmol)4-甲基溴代苯乙醇在碳酸钾(1.1g,8mmol),10mLDMF中反应得到化合物54，285mg白色固体，收率52.8％。
1H NMR(400MHz,CDCl3)δ9.81(s,1H),7.38-7.40(m,2H),7.10-7.17(m,4H),6.91-6.93(m,1H),4.23(t,J＝7.2Hz,2H),3.90(s,3H),3.13(t,J＝7.2Hz,2H),2.31(s,3H)；
13C NMR(100MHz,CDCl3)δ190.9,153.8,149.8,136.3,134.2,130.1,129.3,128.9,126.8,111.4,109.3,69.9,56.0,35.1,21.0.
以(300mg,2mmol)香草醛为原料，采用与制备化合物51相似操作步骤，与(740mg,4mmol)溴代苯乙醇在碳酸钾(1.1g,8mmol),10mLDMF中反应得到化合物55，400mg白色固体，收率78.1％。
1H NMR(400MHz,CDCl3)δ9.83(s,1H),7.39-7.42(m,2H),7.24-7.34(m,5H),6.93-6.95(m,1H),4.28(t,J＝7.6Hz,2H),3.92(s,3H),3.19(t,J＝7.6Hz,2H)；
13C NMR(100MHz,CDCl3)δ191.0,153.8,149.9,137.4,130.2,129.1,128.7,126.8,126.8,111.6,109.4,69.8,56.1,35.6.
以(300mg,2mmol)香草醛为原料，采用与制备化合物51相似操作步骤，与(860mg,4mmol)4-甲氧基溴代苯乙醇在碳酸钾(1.1g,8mmol),10mLDMF中反应得到化合物56，414mg白色固体，收率72.4％。
1HNMR(400MHz,CDCl3)δ9.83(s,1H),7.39-7.42(m,2H),7.19-7.21(m,2H),6.92-6.94(m,1H),6.84-6.86(m,2H),4.23(t,J＝7.6Hz,2H),3.92(s,3H),3.78(s,3H),3.12(t,J＝7.6Hz,2H)；
13C NMR(100MHz,CDCl3)δ191.0,158.5,153.9,149.9,130.1,130.1,129.4,126.8,114.1,111.5,109.4,70.1,56.1,55.3,34.7.
以(380mg,2mmol)4-羟基-3-三氟甲基苯甲醛为原料，采用与制备化合物51相似操作步骤，与(0.55ml,4mmol)溴代苯乙醇在碳酸钾(1.1g,8mmol),10mL DMF中反应得到化合物57，572mg白色固体，收率97.3％。
1HNMR(400MHz,CDCl3)δ9.90(s,1H),8.09-8.10(m,1H),8.00(dd,J＝2.0Hz,8.4Hz,1H),7.24-7.35(m,5H),7.07(d,J＝8.4Hz,1H),4.37(t,J＝7.2Hz,2H),3.17(t,J＝7.2Hz,2H)；
13C NMR(100MHz,CDCl3)δ189.7,137.4,135.1,129.2,128.9,128.6,126.9,112.8,70.3,35.5.
以(380mg,2mmol)4-羟基-3-三氟甲基苯甲醛为原料，采用与制备化合物51相似操作步骤，与(700mg,3mmol)3,4-二甲氧基溴代苯乙醇在碳酸钾(1.1g,8mmol),10mLDMF中反应得到化合物58，670mg白色固体，收率94.6％。
1HNMR(400MHz,CDCl3)δ9.91(s,1H),8.10-8.11(m,1H),8.01(dd,J＝2.0Hz,8.4Hz,1H),7.08(d,J＝8.4Hz,1H),6.83-6.86(m,3H),4.32(t,J＝6.4Hz,2H),3.89(s,3H),3.86(s,3H),3.12(t,J＝6.4Hz,2H)；
13C NMR(100MHz,CDCl3)δ189.7,161.4,149.0,148.0,135.1,130.2,129.4,128.9,121.0,112.8,112.5,111.3,70.6,56.0,55.8,35.2.
以(244mg,2mmol)4-羟基苯甲醛为原料，采用与制备化合物51相似操作步骤，与(555mg,3mmol)溴代苯乙醇在碳酸钾(1.1g,8mmol),10mLDMF中反应得到化合物59，390mg白色固体，收率86.3％。
1HNMR(400MHz,CDCl3)δ9.88(s,1H),7.81-7.83(m,2H),7.28-7.35(m,5H),6.98-7.00(m,2H),4.26(t,J＝6.8Hz,2H),3.13(t,J＝6.8Hz,2H)；
13C NMR(100MHz,CDCl3)δ190.9,163.9,137.7,132.0,130.0,129.0,128.6,126.8,114.8,69.0,35.6.
以(244mg,2mmol)4-羟基苯甲醛为原料，采用与制备化合物51相似操作步骤，与(732mg,3mmol)3,4-二甲氧基溴代苯乙醇在碳酸钾(1.1g,8mmol),10mL DMF中反应得到化合物60，373mg白色固体，收率65.2％。
1HNMR(400MHz,CDCl3)δ9.88(s,1H),7.82(d,J＝6.8Hz,2H),6.99(d,J＝6.8Hz,2H),6.81-6.83(m,3H),4.24(t,J＝6.8Hz,2H),3.89(s,3H),3.87(s,3H),3.08(t,J＝6.8Hz,2H)；
13C NMR(100MHz,CDCl3)δ190.8,163.9,149.0,147.9,132.0,130.3,130.0,121.0,114.8,112.4,111.4,69.23,56.0,55.9,35.2.
实施例1：
步骤B操作:
50mL圆底瓶中装有(50mg,0.14mmol)化合物51，(16mg,0.12mmol)2-吲哚酮，5滴哌啶，乙醇5mL加入，回流反应4h，TLC显示完全，冷却后过滤得47mg化合物1，收率84.8％。
1H NMR(400MHz,CDCl3)δ10.54(s,1H),8.67(s,1H),7.82(d,J＝10.4Hz,1H),7.73(s,1H),7.66(d,J＝7.2Hz,1H),7.17(t,J＝7.6Hz,1H),7.09(d,J＝8.4Hz,1H),6.97(t,J＝7.6Hz,1H),6.82(d,J＝7.6Hz,1H),6.68(s,2H),4.25(t,J＝7.2Hz,2H),3.83(s,3H),3.76(s,6H),3.62(s,3H),3.00(t,J＝6.8Hz,2H)；
13C NMR(100MHz,CDCl3)δ168.0,153.2,150.8,148.6,140.7,137.9,136.5,134.4,128.7,128.0,127.8,126.0,124.4,121.4,119.7,115.7,112.6,109.7,106.9,100.0,69.3,60.5,56.0,35.7,19.1.
HR-MS(ESI)calcd for C27H28O6N(M+H)+:462.1911,found 462.1903.
实施例2：
以(50mg,0.14mmol)化合物51，(18mg,0.12mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物2，黄色固体收率84.2％。
1H NMR(400MHz,CDCl3)δ10.54(s,1H),8.69(s,1H),7.81-7.83(m,2H),7.58(d,J＝9.2Hz,1H),7.11(d,J＝8.8Hz,1H),6.98-7.01(m,1H),6.77-6.80(m,1H),6.68(s,2H),4.25(t,J＝6.8Hz,2H),3.83(s,3H),3.76(s,6H),3.62(s,3H),3.00(t,J＝6.8Hz,2H)；
13C NMR(100MHz,CDCl3)δ168.1,153.1,150.7,148.5,140.7,137.9,136.5,134.4,128.7,128.0,127.8,126.0,124.4,121.4,119.7,115.7,112.6,109.7,106.9,100.0,69.3,60.5,56.0,35.6,19.0.
HR-MS(ESI)calcd for C27H27O6NF(M+H)+:480.1817,found480.1807.
实施例3：
以(50mg,0.14mmol)化合物51,(18mg,0.12mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物3，33mg黄色固体，收率56.9％。
1HNMR(400MHz,CDCl3)δ10.38(s,1H),8.63(s,1H),8.58(s,1H),6.63-7.8(m,9H),4.16-4.22(m,2H),3.83(s,3H),3.76(s,6H),3.62(s,3H),2.95(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C28H30O6N(M+H)+:476.2068,found 476.2065.
实施例4：
以(50mg,0.14mmol)化合物51,(20mg,0.12mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物4，20mg黄色固体，收率33.3％。
1H NMR(400MHz,CDCl3)δ10.28(s,1H),8.62(s,1H),7.78-7.80(m,1H),7.70(s,1H),7.30(s,1H),7.04-7.06(m,1H),6.63-6.71(m,4H),4.20(t,J＝6.8Hz,2H),3.78(s,3H),3.71(s,6H),3.70(s,3H),3.57(s,3H),2.95(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C28H30O7N(M+H)+:492.2017,found492.2007.
实施例5：
以(50mg,0.18mmol)化合物52,(20mg,0.15mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物5，56mg黄色固体，收率95.9％。
1HNMR(400MHz,CDCl3)δ10.48(s,1H),8.61(s,1H),7.59-7.77(m,3H),7.31-7.35(m,2H),6.75-7.14(m,6H),4.19(t,J＝7.6Hz,2H),3.76(s,3H),3.01(t,J＝6.8Hz,2H)；
实施例6：
以(50mg,0.18mmol)化合物52,(20mg,0.15mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物6，44mg黄色固体，收率72.1％。
1HNMR(400MHz,d-DMSO)δ10.50(s,1H),8.63(s,1H),7.76(m,2H),7.53-7.55(m,1H),7.33-7.35(m,2H),7.07-7.11(m,3H),6.92-6.96(m,1H),6.72-6.76(m,1H),4.22(t,J＝6.8Hz,2H),3.77(s,3H),3.02(t,J＝6.8Hz,2H)；
实施例7：
以(50mg,0.18mmol)化合物52,(22mg,0.15mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物7，40mg黄色固体，收率66.7％。
1H NMR(400MHz,CDCl3)δ8.74(m,1H),7.52-7.54(m,1H),7.42-7.45(m,1H),7.25-7.33(m,4H),6.99-7.03(m,3H),6.88-6.90(m,1H),6.72-6.74(m,1H),4.22(t,J＝6.8Hz,2H),3.77(s,3H),3.02(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C25H23O3NF(M+H)+:404.1656,found404.1636.
实施例8：
以(50mg,0.18mmol)化合物52,(25mg,0.15mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，并重结晶两次，得到化合物8，22mg黄色固体，收率34.4％。
1H NMR(400MHz,d-DMSO)δ10.33(s,1H),8.66(s,1H),7.83-7.85(m,1H),7.75(m,1H),7.34-7.40(m,3H),7.08-7.15(m,3H),6.70-6.77(m,2H),4.25(t,J＝6.8Hz,2H),3.82(s,3H),3.76(s,3H),3.06(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C25H23O4NF(M+H)+:420.1606,found420.1600.
实施例9：
以(100mg,0.32mmol)化合物53，(35mg,0.26mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物9，100mg淡黄色固体，收率88.5％。
1H NMR(400MHz,d-DMSO)δ10.54(s,1H),8.67(d,J＝2.0Hz,1H),7.81(dd,J＝2.0Hz,6.8Hz,1H),7.28(s,1H),7.66(d,J＝7.6Hz,1H),7.15-7.19(m,1H),7.08(d,J＝8.4Hz,1H),6.94-6.99(m,2H),6.81-6.88(m,3H),4.21(t,J＝6.8Hz,2H),3.83(s,3H),3.75(s,3H),3.71(s,3H),2.99(t,J＝6.8Hz,2H)；
13C NMR(100MHz,CDCl3)δ167.9,150.8,149.0,148.5,147.9,140.6,137.9,131.0,128.6,127.9,127.7,125.9,124.4,121.4,119.6,115.7,113.5,112.5,112.3,109.7,56.0,55.9,55.8.
实施例10：
以(100mg,0.32mmol)化合物53，(40mg,0.26mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物10，85mg淡黄色固体，收率80.5％。
1H NMR(400MHz,d-DMSO)δ10.51(s,1H),8.65(d,J＝2.0Hz,1H),7.71-7.79(m,2H),7.55(dd,J＝2.0Hz,9.2Hz,1H),7.07(d,J＝9.2Hz,1H),6.92-6.97(m,2H),6.73-6.84(m,3H),4.19(t,J＝7.2Hz,2H),3.79(s,3H),3.71(s,3H),3.67(s,3H),2.96(t,J＝7.2Hz,2H)；
实施例11：
以(100mg,0.32mmol)化合物53，(38mg,0.26mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物11，90mg淡黄色固体，收率53％。
1H NMR(400MHz,d-DMSO)δ10.42(s,1H),8.62-8.66(m,1H),7.81-7.83(m,1H),7.69(s,1H),7.48-7.49(m,2H),7.07-7.09(m,2H),6.83-6.88(m,3H),4.21-4.24(m,2H),3.82(s,3H),3.75(s,3H),3.71(s,3H),2.97-3.01(m,2H),2.29(s,3H)；
HR-MS(ESI)calcd for C27H28O5N(M+H)+:446.1962,found 446.1958.
实施例12：
以(100mg,0.32mmol)化合物53，(38mg,0.26mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物12，重结晶两次后得到55mg淡黄色固体，收率46.6％。
1H NMR(400MHz,d-DMSO)δ10.33(s,1H),8.66(d,J＝2.0Hz,1H),7.83(dd,J＝2.0Hz,8.4Hz,1H),7.75(s,1H),7.34(d,J＝2.0Hz,1H),7.08(d,J＝8.4Hz,1H),6.99(d,J＝1.6Hz,1H),6.84-6.88(m,2H),6.70-6.76(m,2H),4.22(t,J＝7.2Hz,2H),3.82(s,3H),3.76(s,3H),3.75(s,3H),3.71(s,3H),2.99(t,J＝7.2Hz,2H)；
13C NMR(100MHz,d-DMSO)δ168.1,155.1,150.8,149.0,148.5,147.9,138.1,134.5,131.0,128.0,127.7,126.9,124.9,121.3,115.8,114.5,113.5,112.5,112.3,110.2,105.8,69.5,56.1,56.0,55.9,55.8,34.9.
实施例13：
以(60mg,0.22mmol)化合物54，(25mg,0.26mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物13，63mg淡黄色固体，收率87.1％。
1HNMR(400MHz,d-DMSO)δ10.54(s,1H),8.66(d,J＝2.0Hz,1H),7.83(dd,J＝2.0Hz,8.8Hz,1H),7.73(s,1H),7.66(d,J＝7.6Hz,1H),7.21-7.23(m,2H),7.07-7.19(m,4H),6.94-6.98(m,1H),6.82(d,J＝7.6Hz,1H),4.22(t,J＝7.2Hz,2H),3.82(s,3H),3.02(t,J＝7.2Hz,2H),2.26(s,3H)；
实施例14：
以(60mg,0.22mmol)化合物54，(27mg,0.18mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物14，60mg淡黄色固体，收率82.6％。
1H NMR(400MHz,d-DMSO)δ10.55(s,1H),8.68(d,J＝1.6Hz,1H),7.80-7.82(m,2H),7.58(dd,J＝3.0Hz,8.8Hz,1H),7.21-7.23(m,2H),7.09-7.12(m,3H),6.96-7.01(m,1H),6.77-6.80(m,1H),4.23(t,J＝7.2Hz,2H),3.82(s,3H),3.02(t,J＝7.2Hz,2H),2.26(s,3H)；
实施例15：
以(60mg,0.22mmol)化合物54，(26mg,0.18mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物15，60mg淡黄色固体，收率83.4％。
1H NMR(400MHz,d-DMSO)δ10.42(s,1H),8.61-8.66(m,1H),7.81-7.83(m,1H),7.69(s,1H),7.21-7.49(m,7H),6.70(d,J＝8.0Hz,1H),4.20-4.24(m,2H),3.81(m,3H),3.02(t,J＝6.8Hz,2H),2.29(s,3H),2.27(s,3H)；
HR-MS(ESI)calcd for C26H26O3N(M+H)+:400.1907,found 400.1902.
实施例16：
以(60mg,0.22mmol)化合物54，(26mg,0.18mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物16，55mg淡黄色固体，收率72.4％。
1H NMR(400MHz,d-DMSO)δ10.33(s,1H),8.68(d,J＝2.0Hz,1H),7.83(dd,J＝2.0Hz,8.8Hz,1H),7.74(s,1H),7.34(d,J＝3.0Hz,1H),7.21-7.23(m,2H),7.07-7.12(m,3H),6.70-6.77(m,2H),4.22(t,J＝7.2Hz,2H),3.82(s,3H),3.76(s,3H),3.02(t,J＝7.2Hz,2H),2.26(s,3H)；
实施例17：
以(100mg,0.39mmol)化合物55，(44mg,0.33mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物17，106mg淡黄色固体，收率86.5％。
1H NMR(400MHz,d-DMSO)δ10.54(s,1H),8.66(d,J＝2.0Hz,1H),7.82(dd,J＝1.6Hz,7.6Hz,1H),7.73(s,1H),7.66(d,J＝7.6Hz,1H),7.29-7.36(m,4H),7.15-7.24(m,2H),7.09(d,J＝8.4Hz,1H),6.97(t,J＝7.2Hz,1H),6.82(d,J＝8.0Hz,1H),4.26(t,J＝7.2Hz,2H),3.82(s,3H),3.07(t,J＝7.2Hz,2H)；
实施例18：
以(100mg,0.39mmol)化合物55，(44mg,0.33mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物18，77mg淡黄色固体，收率62.9％。
1H NMR(400MHz,d-DMSO)δ10.55(s,1H),8.68(d,J＝2.0Hz,1H),7.80-7.83(m,2H),7.59(dd,J＝2.4Hz,8.8Hz,1H),7.29-7.36(m,4H),7.22-7.34(m,1H),7.11(d,J＝8.4Hz,1H),6.96-7.01(m,1H),6.77-6.80(m,1H),4.27(t,J＝7.2Hz,2H),3.82(s,3H),3.07(t,J＝7.2Hz,2H)；
实施例19：
以(100mg,0.39mmol)化合物55，(49mg,0.33mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物19，94mg淡黄色固体，收率73.4％。
1H NMR(400MHz,d-DMSO)δ10.42(s,1H),8.65(d,J＝2.0Hz,1H),7.82(dd,J＝1.6Hz,8.4Hz,1H),7.69(s,1H),7.49(s,1H),7.20-7.36(m,5H),7.08(d,J＝8.4Hz,1H),6.97(d,J＝8.0Hz,1H),6.70(d,J＝8.0Hz,1H),4.26(t,J＝6.8Hz,2H),3.81(s,3H),3.07(t,J＝7.2Hz,2H),2.29(s,3H)；
13C NMR(100MHz,d-DMSO)δ168.0,150.7,148.5,138.6,138.4,137.5,130.1,129.5,129.0,128.8,127.8,126.8,126.0,124.6,120.2,115.8,112.6,109.4,69.3,56.0,35.4,21.3.
实施例20：
以(100mg,0.39mmol)化合物55，(53mg,0.33mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物20，77mg淡黄色固体，收率59.2％。
1H NMR(400MHz,d-DMSO)δ10.33(s,1H),8.66(d,J＝2.0Hz,1H),7.83(dd,J＝2.0Hz,6.8Hz,1H),7.75(s,1H),7.29-7.36(m,5H),7.20-7.24(m,1H),7.09(d,J＝8.8Hz,1H),6.70-6.77(m,2H),4.26(t,J＝7.2Hz,2H),3.82(s,3H),3.76(s,3H),3.07(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C25H24O4N(M+H)+:402.1700,found 402.1696.
实施例21：
以(80mg,0.28mmol)化合物56，(31mg,0.23mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物21，80mg淡黄色固体，收率86％。
1H NMR(400MHz,d-DMSO)δ10.54(s,1H),8.66(d,J＝2.0Hz,1H),7.81(dd,J＝2.0Hz,8.8Hz,1H),7.72(s,1H),7.65(d,J＝7.6Hz,1H),7.24-7.27(m,2H),7.15-7.19(m,1H),7.07(d,J＝8.8Hz,1H),6.94-6.98(m,1H),6.85-6.89(m,2H),6.81(d,J＝7.6Hz,1H),4.21(t,J＝7.2Hz,2H),3.82(s,3H),3.72(s,3H),3.00(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C25H23O4NNa(M+Na)+:424.1519,found424.1513.
实施例22：
以(80mg,0.28mmol)化合物56，(35mg,0.23mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物22，85mg淡黄色固体，收率87.6％。
1H NMR(400MHz,d-DMSO)δ10.55(s,1H),8.68(d,J＝2.0Hz,1H),7.80-7.82(m,2H),7.58(dd,J＝2.4Hz,8.8Hz,1H),7.24-7.27(m,2H),7.09(d,J＝8.4Hz,1H),6.96-7.01(m,1H),6.85-6.89(m,2H),6.77-6.80(m,1H),4.21(t,J＝7.2Hz,2H),3.82(s,3H),3.72(s,3H),3.00(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C25H23O4NF(M+H)+:420.1606,found 420.1588.
实施例23：
以(80mg,0.28mmol)化合物56，(34mg,0.23mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物23，80mg淡黄色固体，收率83.3％。
1H NMR(400MHz,d-DMSO)δ10.42(s,1H),8.65-8.66(m,1H),7.81-7.83(m,1H),7.69(s,1H),7.47-7.49(m,1H),7.24-7.27(m,2H),7.06-7.08(m,1H),6.96-6.99(m,1H),6.86-6.88(m,2H),6.69-6.71(m,1H),4.21-4.22(m,2H),3.82(s,3H),3.72(s,3H),3.00(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C26H26O4N(M+H)+:416.1856,found 416.1847.
实施例24：
以(80mg,0.28mmol)化合物56，(38mg,0.23mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物24，84mg淡黄色固体，收率84％。
1H NMR(400MHz,d-DMSO)δ10.33(s,1H),8.66(d,J＝2.0Hz,1H),7.83(dd,J＝1.6Hz,8.4Hz,1H),7.74(s,1H),7.24-7.35(m,3H),7.08(d,J＝8.4Hz,1H),6.86-6.88(m,2H),6.70-6.77(m,2H),4.21(t,J＝7.2Hz,2H),3.82(s,3H),3.76(s,3H),3.72(s,3H),3.07(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C26H26O5N(M+H)+:432.1806,found 432.1800.
实施例25：
以(100mg,0.34mmol)化合物57，(28mg,0.28mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物25，48mg淡黄色固体，收率55.8％。
1H NMR(500MHz,d-DMSO)δ10.61(s,1H),8.98(s,1H),8.59(d,J＝8.5Hz,1H),7.82(s,1H),7.67(d,J＝7.5Hz,1H),7.18-7.38(m,7H),6.98(d,J＝7.5Hz,1H),6.82(d,J＝8.0Hz,1H),4.40(t,J＝6.5Hz,2H),3.07(t,J＝6.5Hz,2H)；
HR-MS(ESI)calcd for C24H19O2NF3(M+H)+:410.1362,found 410.1349.
实施例26：
以(100mg,0.25mmol)化合物57，(28mg,0.21mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物26，63mg淡黄色固体，收率79.7％。
1H NMR(400MHz,d-DMSO)δ10.63(s,1H),8.98(d,J＝2.0Hz,1H),8.60(dd,J＝2.4Hz,8.8Hz,1H),7.90(s,1H),7.59(dd,J＝2.4Hz,8.8Hz,1H),7.20-7.41(m,6H),6.99-7.04(m,1H),6.78-6.81(m,1H),4.41(t,J＝6.8Hz,2H),3.82(s,3H),3.07(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C24H18O2NF4(M+H)+:428.1268,found 428.1275.
实施例27：
以(100mg,0.25mmol)化合物57，(32mg,0.22mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物27，77mg淡黄色固体，收率83.7％。
1H NMR(500MHz,d-DMSO)δ10.49(s,1H),8.95(m,1H),8.56-8.61(m,1H),8.07-8.11(m,1H),7.78(s,1H),7.51(s,1H),7.22-7.42(m,6H),7.00-7.01(m,1H),6.70-6.71(m,1H),4.40(m,2H),3.07(t,J＝6.5Hz,2H)；
HR-MS(ESI)calcd for C25H21O2NF3(M+H)+:424.1519,found 424.1515.
实施例28：
以(100mg,0.25mmol)化合物57，(34mg,0.22mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物28，34mg淡黄色固体，收率37.2％。
1H NMR(400MHz,CDCl3)δ8.35(s,1H),7.99(d,J＝1.6Hz,1H),7.76(dd,J＝2.0Hz,8.8Hz,1H),7.71(s,1H),7.26-7.34(m,5H),7.21(s,1H),7.04-7.06(m,1H),6.80(d,J＝1.6Hz,2H),4.32(t,J＝6.8Hz,2H),3.69(s,3H),3.18(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C25H21O3NF3(M+H)+:440.1468,found 440.1458.
实施例29：
以(100mg,0.28mmol)化合物58，(31mg,0.23mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物29，76mg淡黄色固体，收率69.7％。
1H NMR(500MHz,d-DMSO)δ10.61(s,1H),8.98(s,1H),8.60(d,J＝9.0Hz,1H),7.83(s,1H),7.67(d,J＝7.5Hz,1H),7.37(d,J＝9.0Hz,1H),7.19(t,J＝7.5Hz,1H),6.94-7.00(m,2H),6.81-6.88(m,4H),4.37(t,J＝6.0Hz,2H),3.74(s,3H),3.71(s,3H),3.00(t,J＝6.5Hz,2H)；
HR-MS(ESI)calcd for C26H23O4NF3(M+H)+:470.1574,found 470.1566.
实施例30：
以(100mg,0.28mmol)化合物58，(35mg,0.23mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物30，95mg淡黄色固体，收率84.1％。
1H NMR(500MHz,d-DMSO)δ10.63(s,1H),8.99(s,1H),8.61(d,J＝8.5Hz,1H),7.90(s,1H),7.59(d,J＝9.0Hz,1H),7.39(d,J＝9.0Hz,1H),7.00-7.04(m,1H),6.94(s,1H),6.78-6.88(m,3H),4.37(t,J＝6.5Hz,2H),3.73(s,3H),3.71(s,3H),3.00(t,J＝6.5Hz,2H)；
HR-MS(ESI)calcd for C26H22O4NF4(M+H)+:488.1480,found 488.1480.
实施例31：
以(100mg,0.28mmol)化合物58，(34mg,0.23mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物30，95mg淡黄色固体，收率70.8％。
1H NMR(400MHz,d-DMSO)δ10.49(s,1H),8.95(m,1H),8.56-8.61(m,1H),8.07-8.11(m,1H),7.78(s,1H),7.51(s,1H),7.22-7.42(m,5H),7.00-7.01(m,1H),6.70-6.71(m,1H),4.40(m,2H),3.73(s,3H),3.71(s,3H),3.00(t,J＝6.5Hz,2H),2.26(s,3H)；
HR-MS(ESI)calcd for C27H25O4NF3(M+H)+:484.1730,found 484.1710.
实施例32：
以(100mg,0.28mmol)化合物58，(38mg,0.23mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物32，65mg淡黄色固体，收率56％。
1H NMR(400MHz,d-DMSO)δ10.41(s,1H),8.97(s,1H),8.64(d,J＝10.0Hz,1H),7.84(s,1H),7.37-7.39(m,2H),6.71-6.94(m,5H),4.37(t,J＝6.8Hz,2H),3.75(s,3H),3.74(s,3H),3.71(s,3H),3.00(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C27H25O5NF3(M+H)+:500.1679,found 500.1669.
实施例33：
以(80mg,0.35mmol)化合物59，(40mg,0.3mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物33，52mg淡黄色固体，收率75.5％。
1H NMR(400MHz,d-DMSO)δ10.56(s,1H),8.45(d,J＝9.6Hz,2H),7.73(s,1H),7.66(d,J＝7.2Hz,1H),7.29-7.35(m,4H),7.15-7.24(s,2H),7.03(d,J＝8.8Hz,2H),6.96(t,J＝7.6Hz,1H),6.80(d,J＝7.6Hz,1H),4.28(t,J＝6.8Hz,2H),3.00(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C23H20O2N(M+H)+:342.1489,found 342.1484.
实施例34：
以(80mg,0.35mmol)化合物59，(44mg,0.3mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物34，80mg淡黄色固体，收率74％。
1H NMR(400MHz,d-DMSO)δ10.57(s,1H),8.46(d,J＝8.8Hz,2H),7.81(s,1H),7.59(dd,J＝2.8Hz,9.0Hz,1H),7.29-7.35(m,4H),7.20-7.24(m,1H),6.96-7.06(m,3H),6.75-6.79(m,1H),4.29(t,J＝6.8Hz,2H),3.06(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C23H19O2NF(M+H)+:360.1394,found 360.1388.
实施例35：
以(80mg,0.35mmol)化合物59，(44mg,0.3mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物35，30mg淡黄色固体，收率28.3％。
1H NMR(400MHz,CDCl3)δ8.25(s,1H),7.75(s,1H),7.64-7.66(m,2H),7.56(s,1H),7.28-7.36(m,5H),6.97-7.02(m,3H),6.78(d,J＝7.6Hz,1H),4.26(t,J＝6.8Hz,2H),3.15(t,J＝6.8Hz,2H),2.24(s,3H)；
HR-MS(ESI)calcd for C24H22O2N(M+H)+:356.1645,found 356.1631.
实施例36：
以(80mg,0.35mmol)化合物59，(49mg,0.3mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物36，81mg淡黄色固体，收率73％。
1H NMR(400MHz,d-DMSO)δ10.34(s,1H),7.68(d,J＝8.4Hz,2H),7.55(s,1H),7.29-7.35(m,4H),7.20-7.24(m,2H),7.09(d,J＝8.4Hz,2H),6.76-6.83(m,2H),4.28(t,J＝6.8Hz,2H),3.63(s,3H),3.06(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C24H22O3N(M+H)+:372.1594,found 372.1588.
实施例37：
以(80mg,0.27mmol)化合物60，(30mg,0.23mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物37，80mg淡黄色固体，收率88.8％。
1H NMR(400MHz,d-DMSO)δ10.53(s,1H),7.68(d,J＝8.8Hz,2H),7.63(d,J＝8.0Hz,2H),7.56(s,1H),7.18-7.22(m,1H),7.08(d,J＝8.8Hz,2H),6.95(m,1H),6.82-6.89(m,4H),4.25(t,J＝6.8Hz,2H),3.75(s,3H),3.71(s,3H),3.00(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C25H24O4N(M+H)+:402.1700,found 402.1691.
实施例38：
以(80mg,0.27mmol)化合物60，(30mg,0.23mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物38，81mg淡黄色固体，收率89％。
1H NMR(400MHz,d-DMSO)δ10.58(s,1H),7.68(d,J＝8.8Hz,2H),7.63(s,1H),7.34(dd,J＝2.4Hz,8.8Hz,1H),7.11(d,J＝8.8Hz,2H),7.05-7.10(m,1H),6.95-6.96(m,1H),6.83-6.89(m,3H),4.26(t,J＝6.8Hz,2H),3.75(s,3H),3.72(s,3H),3.00(t,J＝6.8Hz,2H)；
HR-MS(ESI)calcd for C25H23O4NF(M+H)+:420.1606,found 420.1596.
实施例39：
以(80mg,0.27mmol)化合物60，(30mg,0.23mmol)5-甲基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物39，89mg淡黄色固体，收率93.2％。
1H NMR(400MHz,CDCl3)δ10.38(s,1H),8.57(s,1H),7.63-7.75(m,3H),7.43-7.49(m,2H),6.79(m,4H),6.71(d,J＝8.0Hz,1H),4.19-4.23(m,2H),3.71(s,3H),3.68(s,3H),2.94-2.98(m,2H),2.14(s,3H)；
HR-MS(ESI)calcd for C26H26O4N(M+H)+:416.1856,found 416.1848.
实施例40：
以(80mg,0.27mmol)化合物60，(38mg,0.23mmol)5-甲氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，得到化合物40，89mg淡黄色固体，收率93.2％。
1H NMR(400MHz,CDCl3)δ10.34(s,1H),7.67-7.69(m,2H),7.55(s,1H),7.20-7.76(m,8H),4.24(t,J＝6.8Hz,2H),3.74(s,3H),3.71(s,3H),3.00(t,J＝6.8Hz,2H)；HR-MS(ESI)calcd for C26H26O5N(M+H)+:432.1806,found 432.1798.
实施例41：
以(38mg,0.23mmol)吲哚-2-酮为原料，采用实施例1相似操作步骤，与(72mg,0.23mmol)(S)-4-((1-(3,4-二甲氧基苯基)-1-丙酮基)-2-氧基苯甲醛在5mL无水乙醇中反应得到化合物41，60mg淡黄色固体，收率61.2％。
实施例42：
化合物41加入15mL甲醇溶解后，滴入硼氢化钠的四氢呋喃溶液，反应2h后淬灭反应，浓缩后柱层析，得到化合物42，40mg淡黄色固体，收率60％。
实施例43：
以(38mg,0.23mmol)3,4-亚甲二氧基吲哚-2-酮为原料，采用实施例1相似操作步骤，与(72mg,0.23mmol)化合物53在5mL无水乙醇中反应得到化合物43，65mg淡黄色固体，收率63.7％。
实施例44：
以(38mg,0.23mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，与(62mg,0.23mmol)4-(3,4-亚甲二氧基苯基乙基)氧基苯甲醛在5mL无水乙醇中反应得到化合物44，80mg淡黄色固体，收率86％。
实施例45：
以(38mg,0.23mmol)5-氟苯并呋喃-2-酮为原料，采用实施例1相似操作步骤，与(72mg,0.23mmol)化合物53在5mL无水乙醇中反应得到化合物45，20mg淡黄色固体，收率20.8％。
实施例46：
以(38mg,0.23mmol)5-氟苯并呋喃-2-酮为原料，采用实施例1相似操作步骤，与(66mg,0.23mmol)4-(3,4-二甲氧基苯基乙基)氨基苯甲醛在5mL无水乙醇中反应得到化合物46，30mg淡黄色固体，收率30％。
实施例47：
以(38mg,0.23mmol)5-氟吲哚-2-酮为原料，采用实施例1相似操作步骤，与(69mg,0.23mmol)4-(3,4-二甲氧基苯基乙基)巯基苯甲醛在5mL无水乙醇中反应得到化合物47，45mg淡黄色固体，收率45％。
实施例48：
以(43mg,0.1mmol)化合物47为原料，与0.1mL过氧化氢在2mL正丙醇，5mL甲醇混合溶剂中室温反应30h后，析出固体，过滤后得到化合物48，得到40mg淡黄色固体，收率90％。
实施例49：
以(37mg,0.08mmol)化合物48为原料，与0.2mL次氯酸钠在3mL乙腈中室温反应10h后，析出固体，过滤得到化合物49，得到30mg淡黄色固体，收率75％。
药理实验
实验例1、木脂素类衍生物MTT法测定肿瘤细胞存活率
(一)方法
MTT法测定肿瘤细胞存活率
将对数生长期的细胞用胰酶消化后，配制成一定浓度的单细胞悬液，根据细胞生长速度的差异，按1500-3000个/孔接种于96孔板，每孔加入细胞悬液100μl。次日加入含不同浓度化合物及相应溶剂对照的新鲜培养基，每孔加100μl(DMSO终浓度<0.1％)，每种受试化合物设3个剂量组(0.5，5，50μmol/L)每组设三个平行孔。于37℃，5％CO2继续培养96h后弃上清，每孔加入50μL新鲜配制的含2.0mg/mL MTT(Sigma Chemical)的无血清培养基。继续培养4h，弃上清，每孔加入150μL DMSO溶解MTT甲簪沉淀，微型振荡器振荡混匀后，酶标仪(WD-2102A,中国)在检测波长570nm条件下测定光密度值(OD)，以溶剂对照处理的肿瘤细胞为对照组，按下列公式计算药物对肿瘤细胞的抑制率，并按中效方程计算IC50：
体外抗肿瘤筛选结果见表
表1体外抗肿瘤筛选结果
HCT116：人结肠癌细胞株
U87-MG：人胶质母细胞瘤细胞株
MGC803:人胃癌细胞株
BGC823：人胃癌细胞株
PC9：人肺癌细胞株
-：未测试。
Claims (10)
1.式(I)化合物或其异构体及其药学上可接受的盐
R1和R2独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，C1-6烷氧羰基，C1-6烷羰基氧基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-6烷基，C1-6烷氧基，三卤C1-6烷基，三卤C1-6烷氧基；
或R1和R2选自-O(CH2)nO-，并与其取代的苯基相连成环；n选自1、2或3；
R3和R4独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，C1-6烷氧羰基，C1-6烷羰基氧基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-6烷基，C1-6烷氧基，三卤C1-6烷基，三卤C1-6烷氧基；
R5选自氢，C1-6烷基，C1-6烷氧基甲基，C0-6烷基胺基；
R6选自氢，羟基，C0-6烷基胺基，C1-6烷羰基氧基，C1-6烷氧基羰基，O＝；
R7，R8，R9，R10，R11独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-6烷基，C1-6烷氧基，三卤C1-6烷基，三卤C1-6烷氧基，C1-6烷氧羰基，C1-6烷羰基氧基，C1-5烷酰基，C1-6烷氧基亚甲基氧基；
或R8和R9选自-O(CH2)n’O-，并与其取代的苯基相连成环；n’选自1、2或3；
X选自O，NH；
Y选自O，NH，S，亚砜，砜。
2.根据权利要求1的化合物或其异构体及其药学上可接受的盐，其特征在于：
R1和R2独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，C1-4烷氧羰基，C1-4烷羰基氧，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-4烷基，C1-4烷氧基，三卤C1-4烷基，三卤C1-4烷氧基；
或R1和R2选自-O(CH2)nO-，并与其取代的苯基相连成环；n选自1、2或3；
R3和R4独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，C1-4烷氧羰基，C1-4烷羰基氧，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-4烷基，C1-4烷氧基，三卤C1-4烷基，三卤C1-4烷氧基；
R5选自氢，C1-4烷基，C1-4烷氧基甲基，C0-4烷基胺基；
R6选自氢，羟基，C0-4烷基胺基，C1-4烷羰基氧基，C1-4烷氧基羰基，O＝；
R7，R8，R9，R10，R11独立的选自氢，卤素，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，C1-4烷基，C1-4烷氧基，三卤C1-4烷基，三卤C1-4烷氧基，C1-4烷氧羰基，C1-4烷羰基氧基，C1-3烷酰基，C1-4烷氧基亚甲基氧基；
或R8和R9选自-O(CH2)n’O-，并与其取代的苯基相连成环；n’选自1、2或3；
X选自O，NH；
Y选自O，NH，S，亚砜，砜。
3.根据权利要求2的化合物或其异构体及其药学上可接受的盐，其特征在于：
R1和R2独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲氧羰基，乙氧羰基，C1-2烷羰基氧基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，甲基，乙基，甲氧基，乙氧基，三卤C1-2烷基，三卤C1-2烷氧基；
或R1和R2选自-OCH2O-，-OCH2CH2O-，并与其取代的苯基相连成环；
R3和R4独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲氧羰基，乙氧羰基，C1-2烷羰基氧基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，甲基，乙基，甲氧基，乙氧基，三卤C1-2烷基，三卤C1-2烷氧基；
R5选自氢，C1-2烷基，C1-2烷氧基甲基，C0-2烷基胺基；
R6选自氢，羟基，O＝，C0-2烷基胺基，C1-2烷羰基氧基，C1-2烷氧基羰基；
R7，R8，R9，R10，R11独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，甲基，乙基，甲氧基，乙氧基，三卤C1-2烷基，三卤C1-2烷氧基，甲氧羰基，乙氧羰基，甲酰基，乙酰基，丙酰基，丁酰基，戊酰基，异丁酰基，2-甲基丁酰基，C1-2烷氧基亚甲基氧基；
或R8和R9选自-OCH2O-，-OCH2CH2O-，并与其取代的苯基相连成环；
X选自O，NH；
Y选自O，NH，S，亚砜，砜。
4.根据权利要求3的化合物或其异构体及其药学上可接受的盐，其特征在于，
R1和R2独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲氧羰基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，甲基，乙基，甲氧基，乙氧基，三氟甲基，三氟甲氧基；
或R1和R2选自-OCH2O-，-OCH2CH2O-，并与其取代的苯基相连成环；
R3和R4独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲氧羰基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，甲基，乙基，甲氧基，乙氧基，三氟甲基，三氟甲氧基；
R5选自氢，甲基，乙基，甲氧基甲基，氨基；
R6选自氢，羟基，O＝，氨基，C1-2烷羰基氧基；
R7，R8，R9，R10，R11独立的选自氢，氟，氯，溴，羟基，二甲胺基，氰基，硝基，甲胺基，甲磺酰基，二甲胺磺酰基，氨基，羧基，甲基，乙基，甲氧基，乙氧基，三氟甲基，三氟甲氧基，甲氧羰基，甲酰基，乙酰基，丙酰基，丁酰基，戊酰基，异丁酰基，甲氧基亚甲基氧基；
或R8和R9选自-OCH2O-，-OCH2CH2O-，并与其取代的苯基相连成环；
X选自O，NH；
Y选自O，NH，S，亚砜，砜。
5.根据权利要求1-4任一项的化合物或其异构体及其药学上可接受的盐，其特征在于，所述化合物选自
6.根据权利要求1-5任一项的化合物或其异构体及其药学上可接受的盐，其特征在于，所述的药学上可接受的盐包括：盐酸盐，氢溴酸盐，磷酸盐，硫酸盐，甲磺酸盐，对甲苯磺酸盐，乙酸盐，三氟乙酸盐，水杨酸盐，氨基酸盐，枸杞酸盐，马来酸盐，酒石酸盐，富马酸盐，柠檬酸盐，乳酸盐，钠盐，钾盐，钙盐，镁盐，锂盐，铵盐或能提供生理上可接受的阳离子的有机碱的盐。
7.制备权利要求1-6任一项的所述化合物的方法，其特征在于，包括以下步骤：
i:取代；ii:缩合；
A.式(II)化合物在碱性条件下与式(III)化合物反应生成式(IV)化合物；
B.式(IV)化合物在有机碱或者无机碱性条件下于醇溶剂中加热反应得到式(I)化合物；
其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，X，Y如权利要求1-6任一项所定义；Z选自：羟基，氯，溴，碘，对甲苯磺酰基，甲磺酰基。
8.一种药物组合物，包括有效剂量的权利要求1-6中任一项的化合物或其异构体及其药学上可接受的盐和药效学上可接受的载体。
9.权利要求1-6中任一项的化合物或其异构体及其药学上可接受的盐在制备预防和/或***的药物中的应用。
10.根据权利要求9的应用，其特征在于，所述的肿瘤选自胶质母细胞瘤、黑色素瘤、胃癌、肺癌、乳腺癌、肾癌、肝癌、口腔上皮癌、***、卵巢癌、胰腺癌、***癌、结肠癌或直肠腺癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110277262.2A CN115073353A (zh) | 2021-03-15 | 2021-03-15 | 木脂素类衍生物及其制法和其药物组合物与用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110277262.2A CN115073353A (zh) | 2021-03-15 | 2021-03-15 | 木脂素类衍生物及其制法和其药物组合物与用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115073353A true CN115073353A (zh) | 2022-09-20 |
Family
ID=83241781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110277262.2A Pending CN115073353A (zh) | 2021-03-15 | 2021-03-15 | 木脂素类衍生物及其制法和其药物组合物与用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115073353A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998007695A1 (en) * | 1996-08-23 | 1998-02-26 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| WO1998050356A1 (en) * | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US20050209195A1 (en) * | 2004-01-20 | 2005-09-22 | Cell Therapeutics Europe S.R.I | Indolinone derivatives |
| CN109896986A (zh) * | 2017-12-07 | 2019-06-18 | 中国医学科学院药物研究所 | 木脂素类天然产物4-o-甲基三白草醇的结构简化物，其制法和其药物组合物与用途 |
| CN111777501A (zh) * | 2019-04-03 | 2020-10-16 | 中国医学科学院药物研究所 | 咖啡酸苯乙酯类衍生物，其制法和其药物组合物与用途 |
-
2021
- 2021-03-15 CN CN202110277262.2A patent/CN115073353A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998007695A1 (en) * | 1996-08-23 | 1998-02-26 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| WO1998050356A1 (en) * | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US20050209195A1 (en) * | 2004-01-20 | 2005-09-22 | Cell Therapeutics Europe S.R.I | Indolinone derivatives |
| CN109896986A (zh) * | 2017-12-07 | 2019-06-18 | 中国医学科学院药物研究所 | 木脂素类天然产物4-o-甲基三白草醇的结构简化物，其制法和其药物组合物与用途 |
| CN111777501A (zh) * | 2019-04-03 | 2020-10-16 | 中国医学科学院药物研究所 | 咖啡酸苯乙酯类衍生物，其制法和其药物组合物与用途 |
Non-Patent Citations (1)
| Title |
|---|
| ACS: ""STN检索报告"", 《数据库REGISTRY（在线）》, pages 1 - 2 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1437346B9 (en) | Benzamide derivatives useful as cell differentiation inducers | |
| ES2259997T3 (es) | Compuestos de indol que contienen sulfonamida. | |
| CN108347942A (zh) | 乙型肝炎核心蛋白调节剂 | |
| US10980809B2 (en) | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | |
| WO2020177744A1 (zh) | 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途 | |
| CN111171049A (zh) | 酪氨酸激酶抑制剂及其用途 | |
| CN110770234A (zh) | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 | |
| JP2022533740A (ja) | メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的ｂｃｌ－２阻害剤 | |
| CN111777501B (zh) | 咖啡酸苯乙酯类衍生物，其制法和其药物组合物与用途 | |
| WO2008087514A2 (en) | Hdac inhibitors | |
| CZ20014637A3 (cs) | Substituované fenoxyoctové kyseliny | |
| CN105585565B (zh) | 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途 | |
| CN106660970A (zh) | 喹唑啉衍生物 | |
| CN111454229B (zh) | 二氢萘并异噁唑类衍生物及其在抗肿瘤药物中的应用 | |
| CN113880772A (zh) | 一类cdk激酶抑制剂及其应用 | |
| WO2023000398A1 (zh) | 一种石蒜碱β-芳基丙烯酸酯衍生物及其制备方法和用途 | |
| CN111943906B (zh) | 脒类衍生物、及其制法和药物组合物与用途 | |
| WO2023202559A1 (zh) | 一种苯基丙烯酸类化合物及其制备方法和应用 | |
| CN110467616B (zh) | 含杂芳基取代哒嗪酮结构的***并吡嗪类化合物的制备及应用 | |
| CN102946882A (zh) | 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途 | |
| CN115073353A (zh) | 木脂素类衍生物及其制法和其药物组合物与用途 | |
| KR20060017544A (ko) | 테트라히드로카르바졸 유도체 및 이의 약제학적 용도 | |
| CN113214138A (zh) | 苯丙酸类衍生物、及其制法和药物组合物与用途 | |
| CN109896986B (zh) | 木脂素类天然产物4-o-甲基三白草醇的结构简化物，其制法和其药物组合物与用途 | |
| US20200325156A1 (en) | Heteroaryl amide compounds, preparation method therefor, pharmaceutical compositions thereof, and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |